Zinc(II)—The Overlooked Éminence Grise of Chloroquine’s Fight against COVID-19?

Autor: Aleksandra Hecel, Małgorzata Ostrowska, Kamila Stokowa-Sołtys, Joanna Wątły, Dorota Dudek, Adriana Miller, Sławomir Potocki, Agnieszka Matera-Witkiewicz, Alicia Dominguez-Martin, Henryk Kozłowski, Magdalena Rowińska-Żyrek
Jazyk: angličtina
Rok vydání: 2020
Předmět:
Zdroj: Pharmaceuticals, Vol 13, Iss 9, p 228 (2020)
Druh dokumentu: article
ISSN: 1424-8247
DOI: 10.3390/ph13090228
Popis: Zn(II) is an inhibitor of SARS-CoV-2′s RNA-dependent RNA polymerase, and chloroquine and hydroxychloroquine are Zn(II) ionophores–this statement gives a curious mind a lot to think about. We show results of the first clinical trials on chloroquine (CQ) and hydroxychloroquine (HCQ) in the treatment of COVID-19, as well as earlier reports on the anticoronaviral properties of these two compounds and of Zn(II) itself. Other FDA-approved Zn(II) ionophores are given a decent amount of attention and are thought of as possible COVID-19 therapeutics.
Databáze: Directory of Open Access Journals
Nepřihlášeným uživatelům se plný text nezobrazuje